使用限进介质色谱柱的柱切换高效液相色谱法直接进样测定大鼠血浆中舒必利

提出一种直接进样测定大鼠血浆中舒必利浓度的高效液相色谱方法,使用限进介质色谱柱作为预柱在线去除血浆蛋白后,将舒必利通过柱切换转移到分析柱中进行分析。限进介质色谱柱为CAPCELLPAKMFSCX阳离子交换柱（20×4．0mmi．d．,5μm）,分析柱为Kromasil C18柱（150×4．6mm i．d．,5μm）,限进介质柱预分离时流动相为PH=6．88的50mmol／L磷酸盐缓冲液乙腈（100：5,V／V）,切换后分析流动相为PH=6．83的50mmol／L磷酸盐缓冲液-乙腈（100：10,V／V）。流速均为1mL／min,检测波长为240nm。该方法检出限为17ng／mL,定量限为50ng／mL。舒必利在50～1400ng／mL之间线性良好（r=0．9997）,高中低浓度的日内、日间相对标准偏差分别为1．5％～4．2％及2．0％～5．2％,方法回收率为98．8％～104．1％．     

高效液相色谱法对吗啡、杜冷丁、安定的同步测定

利用高效液相色谱法同时分析测定了血液中吗啡、杜冷丁、安定的质量浓度。分析柱为C18,流动相为V（甲醇）：V（25mmol／LKH2PO4）＝90：10,检测波长为285nm。样品血液pH8．5～9．4时,用V（氯仿）：V（异丙醇）＝9：1溶液提取,以氮气吹干有机溶剂后用流动相溶解残渣进样分析。线性范围为0．05～50mg／L,最小检出质量浓度为0．05mg／L,日内与日间精密度CV＜6％。     

高效液相色谱法同时测定快安抗感冒液中5种组分的含量

采用高效液相色谱法（HPLC）同时测定快安抗感冒液中对乙酰氨基酚、咖啡因、盐酸甲基麻黄碱、马来酸氯苯那敏和愈创木酚甘油醚的含量。色谱柱为NOVA－PAKC_18柱,流动相为V（已腈）：V（0．03mol／L磷酸氢二铵）：V（0．004mol／L庚烷磺酸钠）：V（三乙胺）=12：44：43．5：0．5,并用磷酸调节pH值至3．0;检测波长220nm,柱温35℃。在此色谱条件下,各组分均获得良好分离。平均回收率为98．0％～100．3％,相对标准偏差小于1．8％。     

高效液相色谱法同时测定快安抗感冒液中5种组分的含量

 采用高效液相色谱法（HPLC）同时测定快安抗感冒液中对乙酰氨基酚、咖啡因、盐酸甲基麻黄碱、马来酸氯苯那敏和愈创木酚甘油醚的含量。色谱柱为NOVA－PAKC_18柱,流动相为V（已腈）：V（0．03mol／L磷酸氢二铵）：V（0．004mol／L庚烷磺酸钠）：V（三乙胺）=12：44：43．5：0．5,并用磷酸调节pH值至3．0;检测波长220nm,柱温35℃。在此色谱条件下,各组分均获得良好分离。平均回收率为98．0％～100．3％,相对标准偏差小于1．8％。     

多功能柱净化-高效液相色谱法检测谷物中的玉米赤霉烯酮

建立了玉米和小麦中玉米赤霉烯酮（ZEN）的多功能柱净化-高效液相色谱检测方法。样品经乙腈-水混合溶剂（V（乙腈）：V（水）=84：16）提取，通过多功能净化柱（MFC）进行一次性净化，以Symmetry^R C18柱为分离柱，甲醇-水（V（甲醇）：V（水）=68：32）为流动相进行高效液相色谱分离和检测。玉米赤霉烯酮的质量浓度在0．01～4．0μg／mL范围内呈良好线性，相关系数为0．9996。检出限为0．04μg／g，在0、04—5．0mg／kg添加范围内的回收率为87．5％～98．6％，相对标准偏差为1．5％～8．3％。     

离子对高效液相色谱法分析注射用新灭菌

建立了离子对高效液相色谱法分离与测定复方制剂（新灭菌）中的羟氨苄青霉素及氟氯青霉素含量法。采用Ｃ８．１０μｍ，４．６×２００ｍｍ柱（大连化物所Ｓｐｈｅｒｉｓｏｒｂ），以含１．４％十六烷基三甲基溴化铵的ｐＨ６．５磷酸盐缓冲液－乙腈（６８＋３２）为流动相，在紫外检测器２５４ｎｍ波长处检测，线性范围为０．２５～２ｍｇ／ｍＬ，ｒ＝０．９９９９（ｎ＝５），羟氨苄青霉素及氟氯青霉素平均回收率分别为９９．５％及１００．７％（ｎ＝５）。精密度：羟氨苄青霉素及氟氯青霉素日内（４ｈ）平均ＲＳＤ（相对标准偏差）均为０．８％（ｎ＝１５），日间（２ｈ）平均ＲＳＤ分别为０．６％和０．７％（ｎ＝３）。     

高效液相色谱法快速测定人血清中丙戊酸含量

建立了血清中丙戊酸的高效液相色谱快速分析法。用ＺｏｒｂａｘＯＤＳ柱,ｐＨ４．２硫酸水溶液为流动相,检测波长２１０ｎｍ,流速０．８ｍＬ／ｍｉｎ,线性范围０．８２μｍｏｌ／Ｌ～１．８ｍｍｏｌ／Ｌ（ｒ＝０．９９６）,最低检测限０．８２μｍｏｌ／Ｌ,平均回收率为９８．３２％±２．２７％,日内与日间的变异系数分别为３．３１％（ｎ＝５）和４．８２％（ｎ＝７）。     

反胶束萃取-高效液相色谱法测定磺酸型偶氮染料

建立了水中磺酸偶氮染料甲基橙（MO）、刚果红（CR）和酸性铬兰K（ACBK）的反胶束萃取-离子对高效液相色谱定量检测的方法。采用Hypersil C18柱（250×4．6mm,5μm）,流动相为V（甲醇）／V（水）=63：37（含10mmol／L的KH2PO4、4mmol／L的四丁基溴化铵,KOH调pH=7．0）,流速为0.8mL／min,MO、CR和ACBK检测波长分别为449nm、505nm和526nm。结果表明,染料的回收率为92．9％～102．1％,相对标准偏差为0．9％～2．3％,水中MO、CR和ACBK的检出限分别为0．6μg／L、1．2μg／L和1．3μg／L。     

毛细管气相色谱法同时测定盐酸氨溴索中甲醇和丙酮的残留量

建立毛细管气相色谱同时测定盐酸氨溴索原料药中甲醇、丙酮两种有机溶刺残留量的方法。两种残留有机溶剂在DB-624毛细管气相色谱柱上均达到良好分离。甲醇和丙酮的线性范围分别为32．54～325．4μg／mL（r=0．9998）、40．68—406．8μg／mL（r=0．9995）,回收率分别为94．7％～101．1％、93．9％～99．1％,检出限分别小于20、10μg／mL,测定结果的相对标准偏差均不大于3．6％（n=5）。     

铅形态的高效液相色谱-电感耦合等离子体质谱分析

用50mm的反相高效液相色谱短柱在V甲醇/VH2O=55／45,其中水相为0．1mol／L乙酸0．1mol／L乙酸铵的缓冲溶液（pH=4．70）,流速0．6mL／min条件下,约10min内实现了无机铅离子（Pb^2＋）、氯化三甲基铅（TML）、氯化三乙基铅（TEL）和氯化三苯基铅（TPhL）的高效液相色谱．电感耦合等离子体质谱（HPLC-ICP-MS）联用分析。4种铅形态在去离子水和自来水中的加标回收率分别为93．8％-115．6％和89．3％-137．8％;峰强度和保留时间的RSD分别为7．4％-14．3％和0．5％-1．3％;仪器检出限及方法检出限分别为0．27-3．07μg/L和1．20-2．33μg／L。     

Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry

A robust and validated LC-MS-MS quantitative method, using column switching and mutiple reaction monitoring was developed for the analysis of risperidone (RIS) and 9-hydroxyrisperidone in human plasma and saliva. The analytical range was 1-100 ng/ml. The method used 25 microl of sample precipitated with 75 microl of acetonitrile containing internal standard (R068808). Analyses were conducted on a PE Sciex API-III + triple quadrupole mass spectrometer fitted with a Turbo IonSpray source. The method was validated for human plasma using EDTA as the anticoagulant and cross-validated to heparinized human plasma and saliva. The recoveries of risperidone and 9-hydroxyrisperidone were 90-93 and 89-93%, respectively. The validated method was applied to clinical samples to study risperidone and 9-hydroxyrisperidone concentrations in plasma and saliva. Risperidone and 9-hydroxyrisperidone appear in the saliva of patients treated with risperidone. Their detection/quantification in saliva provides evidence for recent adherence with therapy.     

HPLC-DAD determination of plasma levels of the antipsychotic risperidone and its main metabolite for toxicological purposes

A new, rapid analytical method, based on liquid chromatography with diode array detection, has been developed and applied to the determination of risperidone and its main active metabolite 9-hydroxyrisperidone in human plasma. The chromatographic separation was obtained on a C8 (150 x 4.6 mm, 5 microm) column, using a mobile phase composed of acetonitrile (27%) and a pH 3.0 phosphate buffer (73%). A sample clean-up procedure was carried out by using C8 cartridges and eluting the analytes with methanol. The extraction yield was highly satisfactory for both analytes, with average absolute recovery values of about 95%. The experimental conditions permitted the quantitative determination of risperidone and 9-hydroxyrisperidone with high precision (RSD < 3.6%) and satisfactory sensitivity (LOQ = 4 ng mL(-1)). The method was applied to plasma samples from a patient who had tried to poison himself with 150 mg of risperidone, and was undergoing polypharmacy.     

Accuracy Profile Theory for the Validation of an LC–MS-MS Method for the Determination of Risperidone and 9-Hydroxyrisperidone in Human Plasma

A sensitive and specific LC–MS-MS method is described for the simultaneous quantification of risperidone and 9-hydroxyrisperidone in human plasma. After extraction with tert-butyl methyl ether, plasma samples were separated on an Atlantis HILIC Silica C18 column (4.6 × 150 mm, 5 μm)with a mobile phase of ammonium formate buffer (10 mM, pH 4.0)/acetonitrile (40/60, v/v). Detection was by MS-MS. The method was fully validated according to the accuracy profile theory. It is based on β-expectation tolerance interval for the total measurement error which includes trueness and intermediate precision. The measurement uncertainty derived from β-expectation tolerance interval was estimated at each of the validation standards. The linearity fitted well over the range of 0.11–26.75 ng mL⁻¹ for risperidone with an LLOQ of 0.11 ng mL⁻¹, and for 9-hydroxyrisperidone, at a range of 0.15–37.8 ng mL⁻¹ with an LLOQ of 0.15 ng mL⁻¹. The intra- and inter-batch precision of risperidone were <5.71 and 8.22%, respectively. For 9-hydroxyrisperidone, the data were 5.78 and 6.48%. The recoveries were 88.78% (risperidone) and 70.35% (9-hydroxyrisperidone). The developed method was applied to a pharmacokinetic study of risperidone.

     

高效液相色谱法测定人血浆中奥氮平的浓度

 用高效液相色谱法测定了人血浆中奥氮平的浓度。色谱条件 :采用岛津LC 6A型高效液相色谱仪 ;色谱柱为ZorbaxODS (15 0mm× 4 6mmi d ,粒径 5 μm) ;流动相为V(5 0mmol/L磷酸钠缓冲液 ,pH 7 2 )∶V(甲醇 )∶V(乙腈 ) =12∶10∶3的溶液 ;检测波长为 2 70nm ;流速为 1 0mL/min ;柱温 40℃ ;灵敏度 0 0 0 5AUFS ;纸速 2mm/min。实验结果显示 ,在上述条件下 ,该方法的线性范围为 15 μg/L～ 12 0 0 μg/L(r =0 9988) ,最低检测限为 3μg/L ,血浆中奥氮平的平均回收率为 (97 0 2± 3 11) % ,测定结果的日内平均相对偏差为 3 86 % (n =15 ) 。     

Accuracy Profile Theory for the Validation of an LC–MS-MS Method for the Determination of Risperidone and 9-Hydroxyrisperidone in Human Plasma

A sensitive and specific LC–MS-MS method is described for the simultaneous quantification of risperidone and 9-hydroxyrisperidone in human plasma. After extraction with tert-butyl methyl ether, plasma samples were separated on an Atlantis HILIC Silica C18 column (4.6 × 150 mm, 5 μm)with a mobile phase of ammonium formate buffer (10 mM, pH 4.0)/acetonitrile (40/60, v/v). Detection was by MS-MS. The method was fully validated according to the accuracy profile theory. It is based on β-expectation tolerance interval for the total measurement error which includes trueness and intermediate precision. The measurement uncertainty derived from β-expectation tolerance interval was estimated at each of the validation standards. The linearity fitted well over the range of 0.11–26.75 ng mL^?1 for risperidone with an LLOQ of 0.11 ng mL^?1, and for 9-hydroxyrisperidone, at a range of 0.15–37.8 ng mL^?1 with an LLOQ of 0.15 ng mL^?1. The intra- and inter-batch precision of risperidone were <5.71 and 8.22%, respectively. For 9-hydroxyrisperidone, the data were 5.78 and 6.48%. The recoveries were 88.78% (risperidone) and 70.35% (9-hydroxyrisperidone). The developed method was applied to a pharmacokinetic study of risperidone.     

Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma

A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) method has been developed and validated for simultaneous quantification of risperidone (RSP) and its active metabolite 9-hydroxyrisperidone (9-OH-RSP) in human plasma. The analytes were extracted from human plasma by using the protein precipitation extraction technique. Methyl risperidone was used as internal standard for RSP and 9-OH-RSP. A Betasil C18 column provided chromatographic separation of analytes followed by detection with mass spectrometry. The mass transition ion-pair was followed as m/z 411.28 --> 191.15 for RSP and m/z 427.30 --> 207.10 for 9-OH-RSP. The method involves a simple extraction, isocratic chromatography conditions and mass spectrometric detection that enable detection at sub-nanogram levels. The proposed method has been validated with a linear range of 0.10-15.0 ng/mL for RSP and 9-OH-RSP. The intrarun and interrun precision and accuracy values were within 15%. The overall recoveries for RSP and 9-OH-RSP were 82.1% and 83.2%, respectively. The total analysis time was as low as 3.0 min only. The developed method was applied for the determination of the pharmacokinetic parameters of RSP and 9-OH-RSP following a single oral administration of a 1 mg RSP tablet in 24 healthy male volunteers.     

安培检测-离子色谱法测定乳品中的微量碘

 用安培检测 离子色谱法检测了乳品中的微量碘。以NaOH作淋洗液 ,直接进样 ,优化了碘的离子色谱分离和测定条件 ,方法的检测限达 1μg/L(3倍信噪比 )。测定了婴儿奶粉、孕产妇专用奶粉和鲜牛奶中的微量碘 ,加标回收率分别为 89 0 % ,86 0 %和 84 1%。     

Simultaneous determination of clozapine, clozapine N-oxide, N-desmethylclozapine, risperidone, and 9-hydroxyrisperidone in plasma by high performance liquid chromatography with ultraviolet detection

A simple high performance liquid chromatography techniques with ultraviolet detection (HPLC–UV) method is described for the simultaneous determination of clozapine (CZP), clozapine N-oxide (CNO), N-desmethylclozapine (NCZ), risperidone (RSP) and 9-hydroxyrisperidone (9-OHRSP) in human plasma. After extraction process, the analytes were separated on a C₁₈ column (150 mm×3.9 mm i.d.) by the mobile phase (methanol–water–dimethylamine, 60:40:0.04 (v:v:v)). Relative recoveries of five analytes were quantitative. The precision and accuracy of intra- and interday assays were all below 8.2% for R.S.D. and 5.6% for RE, respectively. Based on 1 ml of plasma, the limits of detection were 2.0 ng/ml for CZP, 0.2 ng/ml for CZP N-oxide, 1.0 ng/ml for NCZ, 1.0 ng/ml for RSP, and 0.5 ng/ml for 9-OHRSP (S/N=3). The calibration curves were linear (r≥0.988). This method was applied to therapeutic drug monitoring of schizophrenia patients receiving CZP or RSP therapy.     

LC with Column-Switching and Spectrophotometric Detection for Determination of Risperidone and 9-Hydroxyrisperidone in Human Serum

An automated high performance liquid chromatography with column-switching and ultraviolet detection was developed for the analysis of risperidone and 9-hydroxyrisperidone. The method needs minimum sample preparation and is useful for the detection down to a limit of 1 ng mL⁻¹. Sample clean-up of serum was carried out on a CN 20 μm SPE-column using 8% (v/v) acetonitrile in water. Chromatographic separation was performed on ODS Hypersil C18 material with 38% (v/v) acetonitrile and 0.4% (v/v) TEMED in water. Application of the method to the analysis of serum samples confirmed its suitability for therapeutic drug monitoring of risperidone and 9-hydroxyrisperidone.     

Enantioselective fungal biotransformation of risperidone in liquid culture medium by capillary electrophoresis and hollow fiber liquid-phase microextraction

Knowing that microbial transformations of compounds play vital roles in the preparation of new derivatives with biological activities, risperidone and its chiral metabolites were determined by capillary electrophoresis and hollow fiber liquid-phase microextraction after a fungal biotransformation study in liquid culture medium. The analytes were extracted from 1 mL liquid culture medium into 1-octanol impregnated in the pores of the hollow fiber, and into an acid acceptor solution inside the polypropylene hollow fiber. The electrophoretic separations were carried out in 100 mmol/L sodium phosphate buffer pH 3.0 containing 2.0% w/v sulfated-α-CD and carboxymethyl-β-CD 0.5% w/v with a constant voltage of -10 kV. The method was linear over the concentration range of 100-5000 ng/mL for risperidone and 50-5000 ng/mL for each metabolite enantiomer. Within-day and between-day assay precisions and accuracies for all the analytes were studied at three concentration levels, and the values of relative standard deviation and relative error were lower than 15%. The developed method was applied in a pilot biotransformation study employing risperidone as the substrate and the filamentous fungus Mucor rouxii. This study showed that the filamentous fungus was able to metabolize risperidone enantioselectively into its chiral active metabolite, (-)-9-hydroxyrisperidone.